Communiqués Scancell Holdings plc

Actions

SCLP

GB00B63D3314

Recherche biotechnologique et médicale

Marché Fermé - London S.E. 17:35:14 30/09/2026			Varia. 5j.	Varia. 1 janv.
9,400 ^GBX	-1,05%		-3,09%	-5,05%

24/09	Scancell Holdings conclut un accord de facilité de prêt de 25 millions de dollars	MT
19/08	RÉSULTATS ET ACTIVITÉ : Cooks progresse ; Amcomri voit son bénéfice bondir et sa dette reculer	AN

Communiqués

24/09	Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development	AQ
03/09	Scancell to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
28/04	Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study	GL
05/03	Edison Report – Redesigning immunity: The next frontier in immuno-oncology	PU
29/01	Scancell : Financial Year 2026 Interim Results	PU
29/01	H126: solid iSCIB1+ data underpins planned progress	PU
29/01	Interim Results for the six months ended 31 October 2025	GL
26/01	Scancell : FDA clears global Phase III trial for iSCIB1+	PU
26/01	Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma	GL
12/12	SCOPE Data Update: 11 December 2025	PU
09/12	Scancell : Latest SCOPE data confirm durable improvement	PU
09/12	Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma	GL
17/11	Scancell : Abundant development opportunities in immuno-oncology	PU
07/11	Research Update	GL
03/10/25	Scancell : Notice of Annual General Meeting October 2025	PU
11/09/25	Scancell : Financial Year End 2025 Results	PU
11/09/25	Scancell : Full steam ahead with iSCIB1+	PU
11/09/25	Scancell : Annual Report 30th April 2025	PU
11/09/25	Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025	GL
04/08/25	Scancell : SCOPE’ing out iSCIB1+ in advanced melanoma	PU
22/07/25	Scancell : Successful SCOPE outcome and iSCIB1+ selection	PU
22/07/25	Scancell : Active Immunotherapy for a Cancer-Free Future	PU
22/07/25	Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+	GL
22/07/25	Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+	AQ
10/07/25	Scancell : Cancer vaccine data due soon; Glymab developments too	PU